GRAIL/$GRAL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Ticker
$GRAL
Sector
Primary listing
Employees
1,000
Headquarters
Website
GRAIL Metrics
BasicAdvanced
$2.9B
-
-$13.06
-
-
Price and volume
Market cap
$2.9B
52-week high
$103.00
52-week low
$13.58
Average daily volume
1.2M
Financial strength
Current ratio
9.228
Quick ratio
8.764
Long term debt to equity
2.094
Total debt to equity
2.686
Profitability
EBITDA (TTM)
-407.206
Gross margin (TTM)
-56.53%
Net profit margin (TTM)
-329.86%
Operating margin (TTM)
-420.33%
Effective tax rate (TTM)
26.01%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-11.81%
Return on equity (TTM)
-17.68%
Valuation
Price to revenue (TTM)
20.213
Price to book
1.25
Price to tangible book (TTM)
7.31
Price to free cash flow (TTM)
-7.302
Free cash flow yield (TTM)
-13.70%
Free cash flow per share (TTM)
-10.965
Growth
Revenue change (TTM)
22.37%
Earnings per share change (TTM)
-85.93%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Bulls say / Bears say
Q2 2025 total revenue rose 11% year-over-year to $35.5 million, driven by a 22% increase in Galleri screening revenue to $34.4 million and over 45,000 tests sold, indicating robust commercial uptake of the Galleri MCED test. (GRAIL Press Release)
As of June 30, 2025, GRAIL’s cash, cash equivalents, restricted cash and short-term marketable securities totaled $606.1 million, providing funding to support operations and clinical programs into 2028 under current burn guidance. (GRAIL Press Release)
Pre-specified analysis from the PATHFINDER 2 registrational study showed Galleri significantly increased additional cancer detection over the first PATHFINDER study, with improved positive predictive value and maintained high specificity and cancer signal origin accuracy, bolstering its clinical profile. (GRAIL Press Release)
Net loss for Q2 2025 was $114.0 million, reflecting ongoing substantial operating deficits despite impairment-adjusted improvements, underscoring the challenge of reaching profitability. (GRAIL Press Release)
Development services revenue in Q2 2025 declined to $1.2 million from $3.8 million in Q2 2024, a roughly 69% drop, demonstrating limited diversification and reliance on screening revenue. (GRAIL Press Release)
The Galleri test remains a CLIA-regulated laboratory-developed test without FDA clearance, which could delay broader insurance reimbursement and hinder adoption in standard screening protocols. (GRAIL Press Release)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GRAIL stock?
GRAIL (GRAL) has a market cap of $2.9B as of November 08, 2025.
What is the P/E ratio for GRAIL stock?
The price to earnings (P/E) ratio for GRAIL (GRAL) stock is 0 as of November 08, 2025.
Does GRAIL stock pay dividends?
No, GRAIL (GRAL) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next GRAIL dividend payment date?
GRAIL (GRAL) stock does not pay dividends to its shareholders.
What is the beta indicator for GRAIL?
GRAIL (GRAL) does not currently have a Beta indicator.